SlideShare a Scribd company logo
1
 An “Abbreviated new drug application”(ANDA) is an application for a U.S. generic drug
approval for an existing licensed medication or approved drug.
 The termed as “abbreviated” because they generally not required to include preclinical
(animal) and clinical (human) data to establish safety and effectiveness
 An ANDA contains data which is submitted to FDA for the review and potential approval of a
generic drug product. Once approved, an applicant may manufacture and market the generic
drug product to provide a safe, effective, lower cost alternative to the brand-name drug it
references.
 A generic drug product is one that is comparable to an innovator drug product in dosage form,
strength, route of administration, quality, performance characteristics, and intended use.
 Therapeutic Equivalence Evaluations: a drug that has essentially the same effect in the
treatment of a disease as one or more other drugs. All approved products, both innovator and
generic, are listed in FDA's Approved Drug Products with Therapeutic Equivalence
Evaluations.
5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 2
 generic product performs in the same way as the innovator drug is to measure the time it takes
the generic drug to reach the bloodstream in healthy volunteers. This demonstration of
“bioequivalence” gives the rate of absorption, or bioavailability, of the generic drug, which
can then be compared to that of the innovator drug.
 To be approved by FDA, the generic version must deliver the same amount of active
ingredients into a patient's bloodstream in the same amount of time as the innovator drug.
 Basic generic drug requirement are:----
1. Same active ingredient
2. Same route of administration
3. Same dosage form
4. Same strength
5. Same condition of use
6. Inactive ingredient already approved in a similar NDA
5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 3
A. Signed FDA form 356h: Provides information regarding–
1. The applicants name & address,
2. Name of the drug product,
3. The product strength
4. Route of administration,
5. Indication of drug master files cited,
6. Proposed indications,
7. A statement regarding whether the product is for prescription or over the counter.
B. Index: An index should specify volume & page number for each complete & detailed item.
C. Information: Information on the basis for which the ANDA is being submitted.
a) Name of the reference drug, its dosage form & strength.
b) Information on exclusively for the listed drug.
D. Condition for use, including: a) A statement regarding the condition for which the drug will be used.
b) A reference to a noted labeling for the product & the currently approved labeling for the listed drug
product
5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 4
 Active ingredient :
1. Reference drug: A statement that is the same active ingredient compare with Reference
drug.
2. Combination product: this must be shown for both active ingredients.
 Statement: This should include a statement that the route of administration, dosage form &
strength are same as the reference drug.
 Bioequivalence: proposed drug is bioequivalent to the listed drug product.
Labeling
 Include a copy of currently approved labeling for the listed drug as well as the proposed
labeling for the drug being provided for in the ANDA. A side by side comparison of two sets
of labeling is also necessary.
 Chemistry, Manufacturing & Controls: Describe the composition, manufacture,
specifications & analytical procedures for the drug substance & drug product.
1. Human Pharmacokinetics & Bioavailability: This include information concerning
2. The Design
3. The Dosing procedure
4. The number & frequency of blood & urine collection & Methodology for the assay5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 5
 Samples: The sample of the Drug substance & finished product should be provided four
individuals units with sufficient quantities in each unit to permit the FDA to perform all the
tests included in the specifications at least three times.
 Analytical method for drug substance & drug product: This section should consists of the
specifications, analytical method, certificates of analysis, method of analysis, method
validation & stability indicating data as contained in the chemistry, manufacturing & control
part of the application.
 Labeling: 12 specimen of the final printed label & all labeling for the drug product are to be
included.
 Case report forms & tabulations: The need for these should be discussed with appropriate
personnel of the division of bioequivalence prior to submission of the ANDA.
5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 6
 To reduce the price of the drug.
 To reduce the time development.
 Increase the bioavailability of the drug in comparison to references list drug.
5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 7
 Commonly known as “Drug Price Competition & Patent Term Restoration Act” of 1984.
 “The Hatch-Waxman Act: is an act dealing with the approval of generic drugs and
associated conditions for getting their approval from FDA, market exclusivity, rights of
exclusivity, patent term extension and Orange Book Listing.”
 Established bioequivalence: as the basis for approving generic copies of drug products.
These Amendments permit FDA to approve applications to market generic versions of brand-
name drugs without repeating costly and duplicative clinical trials to establish safety and
efficacy. Under the Hatch-Waxman Amendments, brand-name companies gained patent term
extension to account for the time the patented product is under review by FDA and also
gained certain periods of marketing exclusivity. In addition to the ANDA approval pathway,
generic drug companies gained the ability to challenge patents in court prior to marketing as
well as 180-day generic drug exclusivity.
5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 8
 Guidance documents represent the Agency's current thinking on a particular topic. These
documents provide guidelines for the content, evaluation, and ultimate approval of
applications and also to the design, production, manufacturing, and testing of regulated
products for FDA review staff, applicants, and ANDA holders.
 Generic Drugs Guidance's
 Biopharmaceutics Guidance's
 Product-Specific Guidances for Generic Drug Development
5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 9
 The Federal Food, Drug, and Cosmetic Act is the basic food and drug law of the United
States. The law is intended to assure consumers that foods are pure and wholesome, safe to
eat, and produced under sanitary conditions; that drugs and devices are safe and effective for
their intended uses; that cosmetics are safe and made from appropriate ingredients; and that
all labeling and packaging is truthful, informative, and not deceptive.
5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 10
5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 11

More Related Content

What's hot

Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA) Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
SachinRajput94
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
Suhas Reddy C
 
Institutional review board by akshdeep sharma
Institutional review board by akshdeep sharmaInstitutional review board by akshdeep sharma
Institutional review board by akshdeep sharma
Akshdeep Sharma
 
Regulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaRegulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & India
Dr. Pankaj Bablani
 
Ethical guidelines in clinical research @ RxVichuZ!!! ;)
Ethical guidelines in clinical research @ RxVichuZ!!! ;)Ethical guidelines in clinical research @ RxVichuZ!!! ;)
Ethical guidelines in clinical research @ RxVichuZ!!! ;)
RxVichuZ
 
Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]
Sagar Savale
 
NEW DRUG APPLICATION
NEW DRUG APPLICATIONNEW DRUG APPLICATION
NEW DRUG APPLICATION
SACHIN C P
 
institutional review board and independent ethics committee
institutional review board and independent ethics committeeinstitutional review board and independent ethics committee
institutional review board and independent ethics committee
MOHAMMAD ASIM
 
Clinical trial protocol development
Clinical trial protocol developmentClinical trial protocol development
Clinical trial protocol development
SACHIN C P
 
Clinical Trial Safety Monitoring.pptx
Clinical Trial Safety Monitoring.pptxClinical Trial Safety Monitoring.pptx
Clinical Trial Safety Monitoring.pptx
DnyanshreeTijare1
 
GCP for Investigators by Valentyna
GCP for Investigators by ValentynaGCP for Investigators by Valentyna
GCP for Investigators by Valentyna
Valentyna Korniyenko
 
INVESTIGATOR’S BROCHURE (IB)
 INVESTIGATOR’S BROCHURE (IB) INVESTIGATOR’S BROCHURE (IB)
INVESTIGATOR’S BROCHURE (IB)
SachinFartade
 
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
amitsoni240
 
Prescription event monitoring
Prescription event monitoringPrescription event monitoring
Prescription event monitoring
Reyaz Bhat
 
Anda
AndaAnda
Designing of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameedDesigning of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameed
Rumana Hameed
 
Detection, reporting and management of adverse events
Detection, reporting and management of adverse eventsDetection, reporting and management of adverse events
Detection, reporting and management of adverse events
Katla Swapna
 
ind
indind
METHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCEMETHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCE
Dr Arathy R Nath
 
Post marketing surveillance (PMS)
Post marketing surveillance (PMS)Post marketing surveillance (PMS)
Post marketing surveillance (PMS)
Shalini Singh
 

What's hot (20)

Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA) Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
Institutional review board by akshdeep sharma
Institutional review board by akshdeep sharmaInstitutional review board by akshdeep sharma
Institutional review board by akshdeep sharma
 
Regulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaRegulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & India
 
Ethical guidelines in clinical research @ RxVichuZ!!! ;)
Ethical guidelines in clinical research @ RxVichuZ!!! ;)Ethical guidelines in clinical research @ RxVichuZ!!! ;)
Ethical guidelines in clinical research @ RxVichuZ!!! ;)
 
Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]
 
NEW DRUG APPLICATION
NEW DRUG APPLICATIONNEW DRUG APPLICATION
NEW DRUG APPLICATION
 
institutional review board and independent ethics committee
institutional review board and independent ethics committeeinstitutional review board and independent ethics committee
institutional review board and independent ethics committee
 
Clinical trial protocol development
Clinical trial protocol developmentClinical trial protocol development
Clinical trial protocol development
 
Clinical Trial Safety Monitoring.pptx
Clinical Trial Safety Monitoring.pptxClinical Trial Safety Monitoring.pptx
Clinical Trial Safety Monitoring.pptx
 
GCP for Investigators by Valentyna
GCP for Investigators by ValentynaGCP for Investigators by Valentyna
GCP for Investigators by Valentyna
 
INVESTIGATOR’S BROCHURE (IB)
 INVESTIGATOR’S BROCHURE (IB) INVESTIGATOR’S BROCHURE (IB)
INVESTIGATOR’S BROCHURE (IB)
 
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
 
Prescription event monitoring
Prescription event monitoringPrescription event monitoring
Prescription event monitoring
 
Anda
AndaAnda
Anda
 
Designing of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameedDesigning of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameed
 
Detection, reporting and management of adverse events
Detection, reporting and management of adverse eventsDetection, reporting and management of adverse events
Detection, reporting and management of adverse events
 
ind
indind
ind
 
METHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCEMETHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCE
 
Post marketing surveillance (PMS)
Post marketing surveillance (PMS)Post marketing surveillance (PMS)
Post marketing surveillance (PMS)
 

Similar to Abbreviated new drug application submission

Generic drug ppt
Generic drug pptGeneric drug ppt
Generic drug ppt
Ayanpal33
 
IPR NDA and ANDA
IPR NDA and ANDAIPR NDA and ANDA
IPR NDA and ANDA
mahender Kotte
 
Naresh... anda ppt
Naresh... anda pptNaresh... anda ppt
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product development
Sachin G
 
Hatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillanceHatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillance
Moremrunal
 
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfGLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
LokeshThakre6
 
pharma regulatory a
pharma regulatory apharma regulatory a
pharma regulatory a
swapy123
 
Swapnil2
Swapnil2Swapnil2
Swapnil2
swapy123
 
Nda ipr
Nda  iprNda  ipr
Abbreviated New Drug Application ANDA ppt
Abbreviated New Drug Application ANDA pptAbbreviated New Drug Application ANDA ppt
Abbreviated New Drug Application ANDA ppt
Akanksha Puri
 
ANDA -Abbreviated NewDrug Application.pptx
ANDA -Abbreviated NewDrug Application.pptxANDA -Abbreviated NewDrug Application.pptx
ANDA -Abbreviated NewDrug Application.pptx
BHAGYASHRI BHANAGE
 
Brand drug vs generic drug
Brand drug vs generic drugBrand drug vs generic drug
Brand drug vs generic drug
Shubham Paul
 
ANDA
ANDAANDA
ANDA
Siddu K M
 
ANDA , NDA.pptx
ANDA , NDA.pptxANDA , NDA.pptx
ANDA , NDA.pptx
MonishaReddy31
 
Seminar on NDA approval process.pptx
Seminar on NDA approval process.pptxSeminar on NDA approval process.pptx
Seminar on NDA approval process.pptx
PawanDhamala1
 
Anda 120822221703-phpapp01
Anda 120822221703-phpapp01Anda 120822221703-phpapp01
Anda 120822221703-phpapp01
Deshmukh Ishrar
 
ANDA
ANDAANDA
Achyutha anda
Achyutha andaAchyutha anda
Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (
BhanuSriChandanaKnch
 
Anda for generic drugs in Regulatory affairs
Anda for generic drugs in Regulatory affairsAnda for generic drugs in Regulatory affairs
Anda for generic drugs in Regulatory affairs
PreranaHusukale
 

Similar to Abbreviated new drug application submission (20)

Generic drug ppt
Generic drug pptGeneric drug ppt
Generic drug ppt
 
IPR NDA and ANDA
IPR NDA and ANDAIPR NDA and ANDA
IPR NDA and ANDA
 
Naresh... anda ppt
Naresh... anda pptNaresh... anda ppt
Naresh... anda ppt
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product development
 
Hatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillanceHatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillance
 
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfGLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
 
pharma regulatory a
pharma regulatory apharma regulatory a
pharma regulatory a
 
Swapnil2
Swapnil2Swapnil2
Swapnil2
 
Nda ipr
Nda  iprNda  ipr
Nda ipr
 
Abbreviated New Drug Application ANDA ppt
Abbreviated New Drug Application ANDA pptAbbreviated New Drug Application ANDA ppt
Abbreviated New Drug Application ANDA ppt
 
ANDA -Abbreviated NewDrug Application.pptx
ANDA -Abbreviated NewDrug Application.pptxANDA -Abbreviated NewDrug Application.pptx
ANDA -Abbreviated NewDrug Application.pptx
 
Brand drug vs generic drug
Brand drug vs generic drugBrand drug vs generic drug
Brand drug vs generic drug
 
ANDA
ANDAANDA
ANDA
 
ANDA , NDA.pptx
ANDA , NDA.pptxANDA , NDA.pptx
ANDA , NDA.pptx
 
Seminar on NDA approval process.pptx
Seminar on NDA approval process.pptxSeminar on NDA approval process.pptx
Seminar on NDA approval process.pptx
 
Anda 120822221703-phpapp01
Anda 120822221703-phpapp01Anda 120822221703-phpapp01
Anda 120822221703-phpapp01
 
ANDA
ANDAANDA
ANDA
 
Achyutha anda
Achyutha andaAchyutha anda
Achyutha anda
 
Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (
 
Anda for generic drugs in Regulatory affairs
Anda for generic drugs in Regulatory affairsAnda for generic drugs in Regulatory affairs
Anda for generic drugs in Regulatory affairs
 

More from Gaurav Sharma

European medicines evaluation agency
European medicines evaluation agencyEuropean medicines evaluation agency
European medicines evaluation agency
Gaurav Sharma
 
Drug development process
Drug development processDrug development process
Drug development process
Gaurav Sharma
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
Gaurav Sharma
 
Clinical trial public access registries [recovered]
Clinical trial public access registries [recovered]Clinical trial public access registries [recovered]
Clinical trial public access registries [recovered]
Gaurav Sharma
 
Approaches of drug discovery
Approaches of drug discoveryApproaches of drug discovery
Approaches of drug discovery
Gaurav Sharma
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillance
Gaurav Sharma
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or anda
Gaurav Sharma
 
Ma p ps
Ma p psMa p ps
Ma p ps
Gaurav Sharma
 
Inactive ingredients database
Inactive ingredients databaseInactive ingredients database
Inactive ingredients database
Gaurav Sharma
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or anda
Gaurav Sharma
 
Clinical data management
Clinical data managementClinical data management
Clinical data management
Gaurav Sharma
 
Informed consent
Informed consentInformed consent
Informed consent
Gaurav Sharma
 
Investigator's brochure
Investigator's brochureInvestigator's brochure
Investigator's brochure
Gaurav Sharma
 

More from Gaurav Sharma (13)

European medicines evaluation agency
European medicines evaluation agencyEuropean medicines evaluation agency
European medicines evaluation agency
 
Drug development process
Drug development processDrug development process
Drug development process
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
Clinical trial public access registries [recovered]
Clinical trial public access registries [recovered]Clinical trial public access registries [recovered]
Clinical trial public access registries [recovered]
 
Approaches of drug discovery
Approaches of drug discoveryApproaches of drug discovery
Approaches of drug discovery
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillance
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or anda
 
Ma p ps
Ma p psMa p ps
Ma p ps
 
Inactive ingredients database
Inactive ingredients databaseInactive ingredients database
Inactive ingredients database
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or anda
 
Clinical data management
Clinical data managementClinical data management
Clinical data management
 
Informed consent
Informed consentInformed consent
Informed consent
 
Investigator's brochure
Investigator's brochureInvestigator's brochure
Investigator's brochure
 

Recently uploaded

2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
Cambridge Product Management Network
 
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
valvereliz227
 
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
IPLTech Electric
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdfRegistered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
dazzjoker
 
8328958814KALYAN MATKA | MATKA RESULT | KALYAN
8328958814KALYAN MATKA | MATKA RESULT | KALYAN8328958814KALYAN MATKA | MATKA RESULT | KALYAN
8328958814KALYAN MATKA | MATKA RESULT | KALYAN
➑➌➋➑➒➎➑➑➊➍
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
 
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdfThe Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
thesiliconleaders
 
The latest Heat Pump Manual from Newentide
The latest Heat Pump Manual from NewentideThe latest Heat Pump Manual from Newentide
The latest Heat Pump Manual from Newentide
JoeYangGreatMachiner
 
Efficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web ApplicationsEfficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web Applications
Harwinder Singh
 
The Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac SignThe Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac Sign
my Pandit
 
Pitch Deck Teardown: Kinnect's $250k Angel deck
Pitch Deck Teardown: Kinnect's $250k Angel deckPitch Deck Teardown: Kinnect's $250k Angel deck
Pitch Deck Teardown: Kinnect's $250k Angel deck
HajeJanKamps
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
Enhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: IntroductionEnhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: Introduction
Cor Verdouw
 
list of states and organizations .pdf
list of  states  and  organizations .pdflist of  states  and  organizations .pdf
list of states and organizations .pdf
Rbc Rbcua
 
Lukas Rycek - GreenChemForCE - project structure.pptx
Lukas Rycek - GreenChemForCE - project structure.pptxLukas Rycek - GreenChemForCE - project structure.pptx
Lukas Rycek - GreenChemForCE - project structure.pptx
pavelborek
 
High-Quality IPTV Monthly Subscription for $15
High-Quality IPTV Monthly Subscription for $15High-Quality IPTV Monthly Subscription for $15
High-Quality IPTV Monthly Subscription for $15
advik4387
 
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling ServiceDiscover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
obriengroupinc04
 

Recently uploaded (20)

2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
 
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
 
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdfRegistered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
 
8328958814KALYAN MATKA | MATKA RESULT | KALYAN
8328958814KALYAN MATKA | MATKA RESULT | KALYAN8328958814KALYAN MATKA | MATKA RESULT | KALYAN
8328958814KALYAN MATKA | MATKA RESULT | KALYAN
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
 
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdfThe Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
 
The latest Heat Pump Manual from Newentide
The latest Heat Pump Manual from NewentideThe latest Heat Pump Manual from Newentide
The latest Heat Pump Manual from Newentide
 
Efficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web ApplicationsEfficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web Applications
 
The Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac SignThe Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac Sign
 
Pitch Deck Teardown: Kinnect's $250k Angel deck
Pitch Deck Teardown: Kinnect's $250k Angel deckPitch Deck Teardown: Kinnect's $250k Angel deck
Pitch Deck Teardown: Kinnect's $250k Angel deck
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
Enhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: IntroductionEnhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: Introduction
 
list of states and organizations .pdf
list of  states  and  organizations .pdflist of  states  and  organizations .pdf
list of states and organizations .pdf
 
Lukas Rycek - GreenChemForCE - project structure.pptx
Lukas Rycek - GreenChemForCE - project structure.pptxLukas Rycek - GreenChemForCE - project structure.pptx
Lukas Rycek - GreenChemForCE - project structure.pptx
 
High-Quality IPTV Monthly Subscription for $15
High-Quality IPTV Monthly Subscription for $15High-Quality IPTV Monthly Subscription for $15
High-Quality IPTV Monthly Subscription for $15
 
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling ServiceDiscover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
 

Abbreviated new drug application submission

  • 1. 1
  • 2.  An “Abbreviated new drug application”(ANDA) is an application for a U.S. generic drug approval for an existing licensed medication or approved drug.  The termed as “abbreviated” because they generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness  An ANDA contains data which is submitted to FDA for the review and potential approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, lower cost alternative to the brand-name drug it references.  A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics, and intended use.  Therapeutic Equivalence Evaluations: a drug that has essentially the same effect in the treatment of a disease as one or more other drugs. All approved products, both innovator and generic, are listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations. 5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 2
  • 3.  generic product performs in the same way as the innovator drug is to measure the time it takes the generic drug to reach the bloodstream in healthy volunteers. This demonstration of “bioequivalence” gives the rate of absorption, or bioavailability, of the generic drug, which can then be compared to that of the innovator drug.  To be approved by FDA, the generic version must deliver the same amount of active ingredients into a patient's bloodstream in the same amount of time as the innovator drug.  Basic generic drug requirement are:---- 1. Same active ingredient 2. Same route of administration 3. Same dosage form 4. Same strength 5. Same condition of use 6. Inactive ingredient already approved in a similar NDA 5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 3
  • 4. A. Signed FDA form 356h: Provides information regarding– 1. The applicants name & address, 2. Name of the drug product, 3. The product strength 4. Route of administration, 5. Indication of drug master files cited, 6. Proposed indications, 7. A statement regarding whether the product is for prescription or over the counter. B. Index: An index should specify volume & page number for each complete & detailed item. C. Information: Information on the basis for which the ANDA is being submitted. a) Name of the reference drug, its dosage form & strength. b) Information on exclusively for the listed drug. D. Condition for use, including: a) A statement regarding the condition for which the drug will be used. b) A reference to a noted labeling for the product & the currently approved labeling for the listed drug product 5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 4
  • 5.  Active ingredient : 1. Reference drug: A statement that is the same active ingredient compare with Reference drug. 2. Combination product: this must be shown for both active ingredients.  Statement: This should include a statement that the route of administration, dosage form & strength are same as the reference drug.  Bioequivalence: proposed drug is bioequivalent to the listed drug product. Labeling  Include a copy of currently approved labeling for the listed drug as well as the proposed labeling for the drug being provided for in the ANDA. A side by side comparison of two sets of labeling is also necessary.  Chemistry, Manufacturing & Controls: Describe the composition, manufacture, specifications & analytical procedures for the drug substance & drug product. 1. Human Pharmacokinetics & Bioavailability: This include information concerning 2. The Design 3. The Dosing procedure 4. The number & frequency of blood & urine collection & Methodology for the assay5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 5
  • 6.  Samples: The sample of the Drug substance & finished product should be provided four individuals units with sufficient quantities in each unit to permit the FDA to perform all the tests included in the specifications at least three times.  Analytical method for drug substance & drug product: This section should consists of the specifications, analytical method, certificates of analysis, method of analysis, method validation & stability indicating data as contained in the chemistry, manufacturing & control part of the application.  Labeling: 12 specimen of the final printed label & all labeling for the drug product are to be included.  Case report forms & tabulations: The need for these should be discussed with appropriate personnel of the division of bioequivalence prior to submission of the ANDA. 5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 6
  • 7.  To reduce the price of the drug.  To reduce the time development.  Increase the bioavailability of the drug in comparison to references list drug. 5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 7
  • 8.  Commonly known as “Drug Price Competition & Patent Term Restoration Act” of 1984.  “The Hatch-Waxman Act: is an act dealing with the approval of generic drugs and associated conditions for getting their approval from FDA, market exclusivity, rights of exclusivity, patent term extension and Orange Book Listing.”  Established bioequivalence: as the basis for approving generic copies of drug products. These Amendments permit FDA to approve applications to market generic versions of brand- name drugs without repeating costly and duplicative clinical trials to establish safety and efficacy. Under the Hatch-Waxman Amendments, brand-name companies gained patent term extension to account for the time the patented product is under review by FDA and also gained certain periods of marketing exclusivity. In addition to the ANDA approval pathway, generic drug companies gained the ability to challenge patents in court prior to marketing as well as 180-day generic drug exclusivity. 5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 8
  • 9.  Guidance documents represent the Agency's current thinking on a particular topic. These documents provide guidelines for the content, evaluation, and ultimate approval of applications and also to the design, production, manufacturing, and testing of regulated products for FDA review staff, applicants, and ANDA holders.  Generic Drugs Guidance's  Biopharmaceutics Guidance's  Product-Specific Guidances for Generic Drug Development 5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 9
  • 10.  The Federal Food, Drug, and Cosmetic Act is the basic food and drug law of the United States. The law is intended to assure consumers that foods are pure and wholesome, safe to eat, and produced under sanitary conditions; that drugs and devices are safe and effective for their intended uses; that cosmetics are safe and made from appropriate ingredients; and that all labeling and packaging is truthful, informative, and not deceptive. 5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 10
  • 11. 5/21/2019 DR G.K.SHARMA PHARMD, CPPM, CGCPh, DCMS 11